Healthcare Industry News: Medarex
News Release - May 25, 2006
Celldex appoints Thomas Davis, M.D as Chief Medical Officer and Tibor Keler, Ph.D as Chief Scientific OfficerPHILLIPSBURG, NEW JERSEY--(Healthcare Sales & Marketing Network)--May 25, 2006 -- Celldex Therapeutics, Inc ('Celldex'), specialists in developing fully human antibody-based products to target and stimulate the immune system, is pleased to announce the appointments of Thomas Davis, M.D as Chief Medical Officer and Vice President - Clinical Development, and Dr. Tibor Keler as Chief Scientific Officer and Vice President - Research and Development.
Dr. Davis has extensive clinical drug development experience. He previously served as Chief Medical Officer at GenVec, Inc., and as Senior Director of Clinical Science at Medarex, Inc. While at The National Cancer Institute within their Cancer Therapy Evaluation Program (CTEP), he supervised their clinical efforts in adult hematologic malignancies and marrow transplantation as well as their therapeutic antibody portfolio. He trained in Medical Oncology at Stanford University, working with Dr. Ron Levy on the development of rituximab and idiotype vaccines, and trained in medicine at Georgetown University.
At Celldex, Tom will lead the clinical development of the Company's product pipeline directing both clinical development strategy and operations.
Dr. Keler is a scientific founder of Celldex and one of the developers of the Company's Antigen Presenting Cell ('APC') Targeting Technology(TM), which is the core platform technology within Celldex. Before joining Celldex, Tibor led the pre-clinical research activities at Medarex, Inc as Senior Director of Pre-Clinical Development. Before Medarex, he was a researcher at the Institute for Cancer Research, Fox Chase Cancer Center and at the NCI. Tibor continues his role at Celldex directing research, preclinical development and manufacturing.
Robert Burns, President and Chief Executive Officer, said, "The appointment of Tom Davis represents an important addition to our now complete executive team, and reflects the enormous progress of Celldex as we drive multiple clinical programs forward into later stage development. Tibor Keler's appointment as CSO recognizes his major contribution to establishing Celldex as a viable research group. Both Tom and Tibor are experienced, well-established scientists in cancer immunology."
Source: Celldex Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.